Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRC | P12931 | 13/20 | 0.45 |
| ▸ | EGFR | P00533 | 6/20 | 0.45 |
| ▸ | LCK | P06239 | 3/20 | 0.41 |
| ▸ | ABL1 | P00519 | 5/20 | 0.41 |
| ▸ | ABL2 | P42684 | 5/20 | 0.41 |
| ▸ | CA2 | P00918 | 3/20 | 0.40 |
| ▸ | TEK | Q02763 | 2/20 | 0.40 |
| ▸ | KDR | P35968 | 1/20 | 0.40 |
| ▸ | IGF1R | P08069 | 1/20 | 0.38 |
| ▸ | FGR | P09769 | 1/20 | 0.38 |
| ▸ | EPHA1 | P21709 | 1/20 | 0.38 |
| ▸ | TXK | P42681 | 1/20 | 0.38 |
| ▸ | FRK | P42685 | 1/20 | 0.38 |
| ▸ | PTK6 | Q13882 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30941062 | 1.00 | SRC (0.45) | SRCEGFRLCKABL1ABL2 | |
| SCHEMBL25048893 | 1.00 | SRC (0.45) | SRCEGFRLCKABL1ABL2 | |
| SCHEMBL30941076 | 1.00 | SRC (0.45) | SRCEGFRLCKABL1ABL2 | |
| SCHEMBL25048101 | 1.00 | SRC (0.45) | SRCEGFRLCKABL1ABL2 | |
| SCHEMBL25048196 | 0.95 | SRC (0.42) | SRCEGFRLCKABL1ABL2 | |
| SCHEMBL25048543 | 0.95 | SRC (0.42) | SRCEGFRLCKABL1ABL2 | |
| SCHEMBL30941573 | 0.95 | SRC (0.42) | SRCEGFRLCKABL1ABL2 | |
| SCHEMBL25048549 | 0.95 | SRC (0.42) | SRCEGFRLCKABL1ABL2 | |
| SCHEMBL25048864 | 0.95 | SRC (0.43) | SRCEGFRLCKABL1ABL2 | |
| SCHEMBL30941133 | 0.95 | SRC (0.43) | SRCEGFRLCKABL1ABL2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250188110-A1 | SPECIFIC SMALL MOLECULE INHIBITORS THAT BLOCK KMT9 METHYLTRANSFERASE ACTIVITY AND FUNCTION | ALBERT-LUDWIGS-UNIVERSITÄT FREIBURG (DE) | 2025-06-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250188110-A1 | SPECIFIC SMALL MOLECULE INHIBITORS THAT BLOCK KMT9 METHYLTRANSFERASE ACTIVITY AND FUNCTION | KMT5A, KMT5B, KMT5C | SRC 968/4885EGFR 1687/4885LCK 508/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.